Related Experiment Videos
Beneficial antiarrhythmic effect of beta-blockade in patients with dilated cardiomyopathy
1Third Department of Medicine, Kurume University School of Medicine, Japan.
Insights
Beta-blockade therapy effectively suppressed ventricular extrasystoles in 85% of dilated cardiomyopathy patients. This treatment also improved cardiac function and survival rates compared to other antiarrhythmic drugs.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dilated cardiomyopathy (DCM) frequently presents with serious ventricular arrhythmias.
- Effective antiarrhythmic management is crucial for improving outcomes in DCM patients.
Purpose of the Study:
- To compare the antiarrhythmic efficacy of beta-blockade (BB) versus conventional antiarrhythmic agents in patients with DCM.
- To evaluate the impact of BB on left ventricular function and survival rates in this population.
Main Methods:
- Ambulatory Holter monitoring was used to assess ventricular extrasystoles (VEs).
- Patients received either beta-blockade therapy or conventional antiarrhythmic agents.
- Left ventricular fractional shortening and 12-month survival rates were compared between groups.
Main Results:
- Beta-blockade therapy suppressed VEs in 85% of patients, significantly improving Lown's grade or reducing high-grade VEs by over 50%.
- Conventional agents, excluding flecainide and amiodarone, showed poor efficacy in VE suppression.
- BB therapy led to a significant increase in left ventricular fractional shortening (from 16% to 22%) and improved 12-month survival (93% vs. 69%).
Conclusions:
- Beta-blockade demonstrates significant antiarrhythmic potency in patients with dilated cardiomyopathy.
- The antiarrhythmic effects of BB represent an additional therapeutic benefit in managing DCM, particularly in patients with frequent VEs.
- BB therapy improves cardiac function and survival, positioning it as a valuable treatment option for DCM.
Abstract:
Antiarrhythmic effects of beta-blockade (BB) in patients with dilated cardiomyopathy were compared with those of various antiarrhythmic agents using ambulatory Holter monitoring. The BB therapy effectively suppressed ventricular extrasystoles (VEs) in 85% of patients, as evidenced by improvement in Lown's grade or a reduction in the number of the highest grade VEs greater than 50%. In contrast, conventional antiarrhythmic agents, except flecainaid and amiodarone, were poorly effective in suppressing VEs. BB therapy gradually increased left ventricular fractional shortening (16 +/- 6% to 22 +/- 12%) and improved 12-month survival rates as compared with those receiving conventional therapy (93 vs 69%). This antiarrhythmic potency seemed to be an additional therapeutic efficacy of BB in the management of patients with dilated cardiomyopathy, which frequently associated with serious VEs.